Join The Conversation Card Front 01 Copy

The Medtechy Daily: October 8

Posted on October 08, 2018

The Medtechy Daily provides the latest news and insight for the medical technology industry, including medical device, biotech and digital health.

Tweets of the Day


Bose hearing aid gets FDA approval. The FDA recently cleared a new device, the Bose Hearing Aid, which was reviewed under the FDA’s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device. (Medtechy)

Remote patient monitoring cuts hospital admissions, ER visits, report finds. One-fourth of healthcare organizations say remote patient monitoring reduces emergency room visits and hospital readmissions, while 38% say the technology results in fewer inpatient admissions, according to a new KLAS Research report. (Healthcare Dive)

Teleflex Makes an ‘Essential’ Acquisition. Teleflex is making a move to expand its presence in the structural heart and endovascular aneurysm repair markets. To do this, the Wayne, PA-based company is acquiring Essential Medical for an undisclosed sum. (MDDI)

Why CEOs Devote So Much Time to Their Hobbies. When Goldman Sachs named David Solomon its new CEO, the media didn’t just focus on his professional background and his rise through the ranks; it also covered his moonlighting as a bona fide DJ. (Harvard Business Review)

Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says. Biogen’s spinal muscular atrophy med Spinraza hit the market running after its launch, helping fuel growth at the drugmaker as its MS franchise faced a slowdown. Now, the company is touting an interim analysis showing that infants with SMA can benefit "dramatically" from the drug if they’re treated before symptoms develop. (FiercePharma)

Scientists use CRISPR to treat genetic liver diseases in neonatal and adult mice. The newest issue of the journal Nature Medicine features two animal studies that show progress is being made towards achieving the holy grail of gene editing: the ability to prevent or treat diseases that are caused by gene mutations. (FierceBiotech)

The CEO of Merck has an ominous warning for the middlemen who stand between drug makers and patients. Merck CEO Kenneth Frazier thinks something has to change within the pharmaceutical industry to fix the issue of drug pricing.(BusinessInsider)